China's Sinovac, With High-level Government Backing, Could Win Global Race To Market A/H1N1 Vaccine
This article was originally published in PharmAsia News
Executive Summary
BEIJING - With the strong support of China's central government and Beijing health authorities, leading vaccine maker Sinovac Biotech could become the first to cross the finish line in the worldwide race to produce a defense to the A/H1N1 pandemic
You may also be interested in...
China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine
BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic
China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine
BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic
China's Leading Vaccine Developer, Sinovac, Aims To Channel Expanding Earnings Into Acquisitions
BEIJING - While reporting a steep rise in profits for the second quarter of this year, the leadership of Chinese vaccine developer Sinovac Biotech said the cash-rich outfit is screening potential acquisition candidates across China